Of note, DPP-4 inhibitors and GLP-1 agonists have been investigated in human clinical trials to determine if certain T2D treatments are effective in T1D, and the results are promising, but these investigations require larger study sizes and more in-depth evaluation. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.